Tiaprofenic Acid
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Tiaprofenic Acid
Tiaprofenic Acid: Brachydactyly-syndactyly syndrome
One-Sentence Summary
Tiaprofenic acid is a nonsteroidal anti-inflammatory drug (NSAID) originally used for inflammatory and degenerative joint conditions such as rheumatoid arthritis and osteoarthritis. The TxGNN model predicts it may be effective for brachydactyly-syndactyly syndrome, but there are currently 0 clinical trials and 0 publications supporting this prediction. It rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Brachydactyly-syndactyly syndrome |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, tiaprofenic acid is a propionic acid-derivative NSAID, presumed to act through cyclooxygenase (COX) inhibition. Its use in rheumatoid arthritis and osteoarthritis rests on reducing inflammatory pain and stiffness.
Brachydactyly-syndactyly syndromes are congenital limb malformations, generally driven by developmental gene mutations (for example, HOXD13 and related pathways). COX inhibition is not expected to correct a structural genetic defect, so no plausible mechanistic link has been established. The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Other Predictions Reviewed
Nine other predictions were reviewed, and all are also at evidence level L5 with no trials or literature:
| Predicted Indication | TxGNN Score | Assessment |
|---|---|---|
| Pseudoachondroplasia | 0.9998 | Limited and indirect. Early-onset joint degeneration might allow symptomatic pain relief, but the underlying disease would not be modified. |
| Myosclerosis | 0.9999 | Weak and speculative. Fibrosis is not primarily driven by prostaglandin pathways. |
| Brachyolmia-amelogenesis imperfecta syndrome, brachyolmia, acromesomelic dysplasia (Hunter-Thompson type), colobomatous microphthalmia-rhizomelic dysplasia syndrome | 0.9999 to 0.9998 | No mechanistic link. These are genetic developmental disorders that NSAIDs do not address. |
| Factor 5 excess with spontaneous thrombosis, heparin cofactor 2 deficiency | 0.9998 | No therapeutic link, and a safety concern. NSAIDs affect platelet function and carry cardiovascular and bleeding cautions in prothrombotic conditions. |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02179679 | TEVA-TIAPROFENIC ACID | Not specified | Not specified |
| 02179687 | TEVA-TIAPROFENIC ACID | Not specified | Not specified |
Both licences are valid single-ingredient products.
Safety Considerations
Please refer to the package insert for safety information.
No drug-interaction records were found in the data compiled for this report. Because NSAIDs can affect platelet function and carry cardiovascular and bleeding-related cautions, any use in a prothrombotic condition would need careful risk assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, brachydactyly-syndactyly syndrome, has no clinical, literature, or mechanistic support. Its score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. A congenital developmental defect is unlikely to respond to COX inhibition.
To proceed, the following is needed:
- Package insert warnings and contraindications from Health Canada, which are required before any safety screening
- Mechanism of action data for tiaprofenic acid
- A targeted literature search on tiaprofenic acid in axial spondyloarthritis, the only prediction with a coherent rationale
- Evidence of any clinical benefit before reconsidering the brachydactyly-syndactyly prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.